Northwest Biotherapeutics Inc
NWBO
Get informed when a big investor buys or sells
+ FollowMarket Cap$295.8M
Close$
$-0.14
187% downside
Current Fair Value
187% downsideOvervalued by 187% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $295.80 Million |
|---|---|
| Enterprise Value | $358.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | -0.63 |
| Outstanding Shares | 1,584,843,000 |
Return
| Return on Equity | 119.87% |
|---|---|
| Return on Assets | -56.99% |
| Return on Invested Capital | 1814.00% |
Valuation & Multiples
| P/E Ratio | -5.9 |
|---|---|
| PEG | 7.14 |
| Price to Sales | - |
| Price to Book Ratio | -0.17 |
| Enterprise Value to Revenue | 239.15 |
| Enterprise Value to EBIT | -6.75 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | -1.68 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▲ 0.01% |
|---|---|
| Total Invested | $83,294▲ 90.77% |
| Investors Holding | 6▲ 1.00% |
ESG Score
No data
About Northwest Biotherapeutics Inc
CEO: Linda Powers